Numab Therapeutics is a biopharmaceutical company focused on the discovery and development of next-generation multispecific antibody-based therapeutics for inflammation and oncology. With over a decade of innovation, Numab has built a highly differentiated multispecific antibody platform integrating λ-cap™ and MATCH™ technologies, advanced Fc engineering, and integrated immunogenicity-reduction strategies. Leveraging deep in-house engineering expertise, Numab is advancing a diversified pipeline of multispecific antibodies with first- and best-in-class potential and has established a strong track record of strategic partnerships with leading pharmaceutical companies.
Looking for a particular Numab Therapeutics AG employee's phone or email?
The Numab Therapeutics AG annual revenue was $17.1 million in 2026.
David Urech is the CEO of Numab Therapeutics AG.
64 people are employed at Numab Therapeutics AG.
Numab Therapeutics AG is based in Wädenswil, Zurich.
The NAICS codes for Numab Therapeutics AG are [541, 339, 33, 54].
The SIC codes for Numab Therapeutics AG are [382, 38, 873, 87].